RCKT (Rocket Pharmaceuticals) Interest Expense : $-1.88 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Rocket Pharmaceuticals's interest expense for the three months ended in Sep. 2024 was $ -0.47 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.88 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Rocket Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $ -69.42 Mil. Rocket Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $ -0.47 Mil. Rocket Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rocket Pharmaceuticals Interest Expense Historical Data

The historical data trend for Rocket Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Interest Expense Chart

Rocket Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-5.96

-7.55

-5.89

-1.91

-1.88

Rocket Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.47	-0.47	-0.47	-0.47	-0.47

Rocket Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.88 Mil.

Rocket Pharmaceuticals (NAS:RCKT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rocket Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $-0.47 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-69.42 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $22.80 Mil.

Rocket Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Rocket Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Rocket Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

9IP1:Germany 9IP1:Germany

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Executives

Martin Wilson	officer: General Counsel	C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Gaurav Shah	director, officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
John Militello	officer: See Remarks	C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Kinnari Patel	officer: Chief Operating Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White	officer: Chief Medical Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
David P Southwell	director, officer: See Remarks	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Gotham Makker	director	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Jonathan David Schwartz	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carlos Garcia-parada	officer: Chief Financial Officer	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork	director	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam	officer: SVP - Finance & PFO	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Naveen Yalamanchi	director	412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder	officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016